We are live on
!
Find out more
VEA
Virtus ETF Advisers Portfolio holdings
AUM
$215M
1-Year Est. Return
53.68%
This Fund
S&P 500
This Quarter
Est. Return
+4.68%
1 Year Est. Return
+53.68%
3 Year Est. Return
+121.72%
5 Year Est. Return
+144.54%
10 Year Est. Return
+633.35%
AUM
$223M
AUM Growth
-$41.4M
(-16%)
Cap. Flow
-$38.1M
Cap. Flow
% of AUM
-17.06%
Top 10 Holdings %
Top 10 Hldgs %
11%
Holding
420
New
44
Increased
50
Reduced
231
Closed
47
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
The Mosaic Company
MOS
|
+$2.06M |
| 2 |
Petrobras
PBR
|
+$2M |
| 3 |
Vale
VALE
|
+$1.96M |
| 4 |
Cheniere Energy
CQP
|
+$1.94M |
| 5 |
STR
Sitio Royalties
STR
|
+$1.94M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Boise Cascade
BCC
|
+$2.62M |
| 2 |
Extra Space Storage
EXR
|
+$2.49M |
| 3 |
Canadian Natural Resources
CNQ
|
+$2.46M |
| 4 |
Imperial Oil
IMO
|
+$2.45M |
| 5 |
Avient
AVNT
|
+$2.42M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Materials | 20.16% |
| 2 | Real Estate | 20.02% |
| 3 | Healthcare | 16.51% |
| 4 | Energy | 10.55% |
| 5 | Utilities | 10.47% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
326
Caribou Biosciences
CRBU
$146M
| $86K | 0.04% |
9,392
-557
| -6% | -$5.87K |
|
|
KRON
327
DELISTED
Kronos Bio
KRON
| $86K | 0.04% |
11,844
-704
| -6% | -$6K |
|
328
Alaunos Therapeutics
TCRT
$4.64M
| $86K | 0.04% |
876
-52
| -6% | -$6.67K |
|
329
Quince Therapeutics
QNCX
$21.5M
| $85K | 0.04% |
68
-4
| -6% | -$5.44K |
|
|
CMPS
330
Compass Pathways
CMPS
$1.47B
| $84K | 0.04% |
6,524
-389
| -6% | -$5.8K |
|
331
MacroGenics
MGNX
$233M
| $84K | 0.04% |
9,556
-564
| -6% | -$6.23K |
|
332
Nuvation Bio
NUVB
$2.29B
| $84K | 0.04% |
16,034
-952
| -6% | -$5.35K |
|
333
Curis
CRIS
$9.71M
| $83K | 0.04% |
87
-5
| -5% | -$6.38K |
|
334
Lexicon Pharmaceuticals
LXRX
$1.03B
| $82K | 0.04% |
39,262
-2,322
| -6% | -$6.44K |
|
|
EPIX
335
DELISTED
ESSA Pharma
EPIX
| $80K | 0.04% |
12,885
-758
| -6% | -$6.66K |
|
336
IDEAYA Biosciences
IDYA
$3.43B
| $80K | 0.04% |
7,192
-430
| -6% | -$6.34K |
|
337
Nurix Therapeutics
NRIX
$2.45B
| $80K | 0.04% |
5,676
-334
| -6% | -$5.93K |
|
338
Scholar Rock
SRRK
$5.88B
| $80K | 0.04% |
6,212
-366
| -6% | -$6.25K |
|
339
AtaiBeckley Inc
ATAI
$2.66B
| $79K | 0.04% |
15,469
-924
| -6% | -$5.14K |
|
|
CVAC
340
DELISTED
CureVac
CVAC
| $79K | 0.04% |
4,028
-230
| -5% | -$4.59K |
|
341
Edgewise Therapeutics
EWTX
$4.28B
| $79K | 0.04% |
8,129
-475
| -6% | -$6.11K |
|
342
Shattuck Labs
STTK
$646M
| $79K | 0.04% |
18,546
-1,102
| -6% | -$6.25K |
|
343
CEL-SCI Corp
CVM
$19.9M
| $77K | 0.03% |
654
-39
| -6% | -$6.35K |
|
344
Vor Biopharma
VOR
$1.06B
| $76K | 0.03% |
629
-37
| -6% | -$6.3K |
|
|
LENZ
345
LENZ Therapeutics
LENZ
$179M
| $76K | 0.03% |
2,138
-127
| -6% | -$7.95K |
|
346
Olema Pharmaceuticals
OLMA
$977M
| $73K | 0.03% |
17,135
-1,015
| -6% | -$5.59K |
|
347
Passage Bio
PASG
$14.5M
| $72K | 0.03% |
1,166
-69
| -6% | -$5.69K |
|
348
Pliant Therapeutics
PLRX
$65M
| $72K | 0.03% |
10,224
-603
| -6% | -$6.15K |
|
349
Taysha Gene Therapies
TSHA
$1.61B
| $71K | 0.03% |
10,878
-641
| -6% | -$4.79K |
|
|
KLRS
350
Kalaris Therapeutics
KLRS
$80.9M
| $71K | 0.03% |
455
-27
| -6% | -$5.39K |
|
Similar funds
NCM
SSA
LIWM
VFG
IAM
1M
GC
RC
Virtus ETF Advisers's Q1 2022 Portfolio in Review
As of Q1 2022, Virtus ETF Advisers held 420 positions worth $223M, down 16% from $265M the previous quarter. Its ten largest holdings account for 11% of the portfolio.
Virtus ETF Advisers withdrew a net $38.1M in Q1 2022, closing 47 positions and reducing 231 holdings. Its most notable exit was Boise Cascade, an estimated $2.62M position sold in full.
By sector, the portfolio is most concentrated in Materials at 20% of assets, up from 14% a quarter earlier, followed by Real Estate and Healthcare.
Against the trend, Virtus ETF Advisers opened a new position in The Mosaic Company worth $2.75M.
- Virtus ETF Advisers's largest Q1 2022 buy was The Mosaic Company: 41,283 shares worth $2.75M.
- Virtus ETF Advisers added most to Agnico Eagle Mines in Q1 2022, an estimated $1.28M increase.
- Virtus ETF Advisers's biggest Q1 2022 reduction was Gold Fields, cutting an estimated $1.09M.
- Virtus ETF Advisers fully exited Boise Cascade in Q1 2022, selling an estimated $2.62M.
- Virtus ETF Advisers's ten largest holdings make up 11% of its $223M portfolio in Q1 2022.
- Virtus ETF Advisers opened 44 new positions and closed 47 in Q1 2022.
- Virtus ETF Advisers's portfolio value fell 16% quarter-over-quarter to $223M.
Based on Virtus ETF Advisers's 13F filing for Q1 2022, filed 16 May 2022.